Teva Pharmaceuticals has agreed to pay $35 million and withdraw six patents from a U.S. regulatory list to settle claims that ...
TipRanks on MSN
Upstream Bio’s Verekitug Study: A Potential Game-Changer for Severe Asthma Treatment
Upstream Bio, Inc. (($UPB)) announced an update on their ongoing clinical study. Upstream Bio, Inc. is conducting a study titled ‘A Long-Term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback